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Background: The clinical use and prognostic value of plasma brain natriuretic peptide (NT-
proBNP) and soluble suppression of tumourigenicity-2 (sST2) levels are not known in 
patients with repaired Tetralogy of Fallot (rTOF). 
 
Objectives: We evaluated blood biomarkers in rTOF patients by combining the available 
evidence, focussing on prognosis, adverse echocardiographic findings and exercise intolerance. 
 
Methods: This systematic review and meta-analysis were carried out in accordance with the 
preferred reporting items for systematic reviews and meta-analysis (PRISMA) guidelines. For 
the primary prognostic outcomes, a meta-analysis was performed. For hemodynamic 
outcomes, a pooled meta-analysis of correlation coefficients (r) was performed. The study 
protocol was registered with PROSPERO(CRD42020211897). 
 
Results:  We analysed 1479 patients with repaired TOF in 23 studies. Mean age was 22.7±8.3 
years. The mean value of NT-proBNP was 174.4.1±56.4 pg/ml while ST2 drawn from two 
investigations was 26.95 ng/ml. There was no difference in mean NT-proBNP between older 
and younger subjects (160.4 ±37.7 vs190.6 ±72.9, pg/ml, respectively; p>.05). NT-proBNP 
levels were higher in TAP studies than others with other RVOT intervention (191.6± 57 vs 
151±46, pg/ml, p<.05). Elevated NT-proBNP levels were associated with an increased  risk of 
adverse cardiovascular outcomes including death, arrhythmias and acute heart failure with a 
hazard ratio (HR) of 1.18(95% CI 1.07-1.31, p.001). We noted a moderate correlation between 
NT-proBNP levels and exercise intolerance, RV structural and volumetric changes (r= -.52, 
r=.41, P<.001).  
Conclusions: NT-proBNP levels are elevated in patients with surgically repaired TOF and 
are associated with an increased risk of cardiovascular adverse outcomes and exercise 
intolerance.  
Key words: Repaired Tetralogy of Fallot; Natriuretic peptide; NT-proBNP; Transannular 
patch; Right ventricle.  




































































Abbreviation and Acronyms 
 
rTOF: repaired Tetralogy of Fallot 
NT-proBNP: Plasma brain natriuretic peptide 
sST2: soluble suppression of tumourigenicity-2 
RV: Right ventricle 
LV: Left ventricle 
PR: Pulmonary regurgitation  
TAP: Transannular patch  
RVD: Right ventricular dimension  
RVEDV: Right ventricular end diastolic volume 























































































Despite 90% long term survival in patients with repaired TOF (rTOF), an increasing number 
of late complications are present such as right and left ventricular dysfunction, arrhythmia and 
exercise intolerance related to residua which dictate the need for reintervention (1-4). The 
degree of pulmonary regurgitation and its relationship to right ventricle (RV) remodelling and 
symptoms is variable but, in some cases, leads to the development of life-threatening atrial and, 
ventricular arrhythmias and sudden cardiac death (2,5).  
 
 Clinical management is aimed at identifying patients at risk who need intervention. Symptoms 
are a poor guide to selection as the majority of adult survivors of TOF are asymptomatic (3,6). 
Using blood biomarkers such as plasma brain natriuretic peptide (NT-proBNP) and soluble 
suppression of tumourigenicity-2 (sST2) is an emerging adjunct to the existing tools to predict 
disease progression and potentially could help identify appropriate patients for intervention. 
NT-proBNP is known to be elevated in asymptomatic patients with repaired TOF compared to 
other types of congenital heart disease (CHD) (7-11), however, clear data about the usefulness 
in diagnostics and prognostication in this population is not yet available. 
 
In order to better understand the relationship between NT-proBNP and sST2 in patients with 
repaired TOF, we undertook this systematic review and meta-analysis to combine the available 







































































Material and Methods 
Systematic review and meta-analysis 
The systematic review and meta-analysis were carried out in accordance with the preferred 
reporting items for systematic reviews and meta-analysis (PRISMA) guidelines. The protocol 
of this study was previously published and registered in the international Prospective Register 
of Systematic reviews (PROSPERO) (CRD42020211897). The flow diagram in figure 1 
demonstrates the literature search based on the PRISMA guidelines.  
 
Inclusion and exclusion criteria  
This review was limited to studies published in English. Inclusion criteria were (a) 
prospectively or retrospectively conducted cohort, cross sectional, single and multicenter 
studies; (b) Blood biomarkers included in methodology and; (c) adult and adolescent patients 
with repaired TOF. Studies excluded from the review were those (a) without blood biomarkers 
data; (b) not published in English and; (c) non rTOF.   
 
Information sources and search strategy  
A comprehensive retrospective search of the literature was conducted using databases 
including MEDLINE, Pubmed, EBM review- Cochrane Database of systematic review, Wiley 
Online library and EBM reviews, utilising a combination of the following search keywords: 
“blood biomarkers in Tetralogy of Fallot’”, “NT-proBNP in TOF”, “sST2 in adult survivors of 
TOF “,’’ Pro-brain natriuretic peptide in CHD’’, “Severe pulmonary regurgitation and blood 





































































Study selection and eligibility criteria  
The following steps were performed (figure 1). (1) Identification of titles through database 
searching. (2) Removal of duplicates. (3) Titles and abstracts screening. (4) Full text sources 
for further screening. (5) studies which gave outcomes were selected for quantitative analysis. 
The primary end points of the study were (a) levels of NT-proBNP in patients with repaired 
TOF; (b) prognostic value of NT-proBNP to composed major cardiovascular outcomes 
(MACE), defined as the occurrence of acute heart failure, arrhythmias or death from any cause. 
The secondary end points were (a) association of elevated NT-proBNP levels with 
hemodynamic echocardiographic changes and to exercise capacity into pooled meta-analysis.  
 
Data extraction 
Data collected by one reviewer (S.A) who determined the eligibility of the studies, according 
to the preferred reporting items for systematic reviews and meta-analysis (PRISMA) 
guidelines, and verified by a second expert reviewer (G.L). To prevent bias, the screening was 
performed independently. The following data were extracted: first author’s name, country, year 
of publication, number of patients included, study design, age, plasma NT-proBNP levels, sST2 
when available, correlation coefficients (r) and the conclusion together with main findings of 
the study. For prognostic analysis, hazard ratios, outcomes measure (mortality or major adverse 










































































Studies were divided into (i) those that reported in an adult population and (ii) those reported 
in a population younger than 18 years old. For the continuous outcome variables, data were 
presented as mean differences (MD) ± standard deviation. Statistical analyses for the primary 
results were conducted using SPSS statistics version 26 (IBM corp, London, United Kingdom). 
For the prognostic studies, a comprehensive meta-analysis was performed using Review 
Manager (version 5.4, Copenhagen: The Nordic Cochrane Centre, The Cochrane 
Collaboration, 2012). The generic inverse variance method was used to combine log hazard 
ratios (log HR) and standard errors of the log HR (SElogHR).  A fixed-effects model was used 
to pool the log hazard ratios and 95% confidence interval for all-cause mortality in each study.  
 
For the secondary outcomes, a pooled meta-analysis of correlation coefficients (r) (random 
effects) using MedCalc (MedCalc software, Belgium, Version 19.6.4) was performed. We 
pooled the values of correlation coefficients and number recruited in each study. The appraisal 
of the heterogeneity among studies was conducted via the Q statistics and I2 statistics, with a 
value of 0%–24.9% considered insignificant, 25%–49.9% mild, 50%–74.9% moderate, and 
≥75% considered severe (12). Publication bias was evaluated by the Begg's test and Egger's 
test, and a P value <.05 indicated potential publication bias. All p values were two tailed, and 








































































The methodological quality of the individual studies was evaluated using the Newcastle-
Ottawa Scale (NOS) (13). Each study was judged on eight items, categorised into three groups: 
cohort selection, the comparability of the groups and the outcome. Stars were awarded for each 
item, with a maximum score of 9. It assigns a maximum of 4 stars for selection, 2 stars for 
comparability, and 3 stars for exposure/outcome assessment. Studies with <5 stars were 
considered low quality, 5–7 stars moderate quality, and >7 stars high quality (table 1). The 




We assessed publication bias by visual inspection of the funnel plot of all included studies. The 
absence of any asymmetric distribution suggested there was no publication bias. In the 
subgroup analysis of the comprehensive correlation meta- analysis, Begg's test and Egger's test 
were used to assess the possibility of publication bias in our analysis and any p value <0.05 











































































Literature search outcomes 
The literature search identified a total of 300 potentially eligible studies. After the exclusion of 
irrelevant studies, 224 were screened thoroughly through abstract and/or full text. 99 articles 
were excluded due to duplication. Of the remaining 125 articles, 50 articles were excluded, as 
they did not meet the inclusion criteria. Full text article assessment was performed for the 
remaining 75 articles and 52 articles were further excluded due to unavailability of the full text, 
leading to a total of 23 articles included in this review. Figure 1 shows the PRISMA flow chart 
for the systematic selection of studies during the literature search. 
 
Characteristics of selected studies 
Of the 23 articles, 13 (57%) reported adult survivors of rTOF (14-26), while 10 studies (43%) 
were reported on a younger group (27-36). 4 studies (17%) were cross-sectional studies 
(16,20,22,24), and 19 studies (83%) were cohort studies (14,15,17-19,21,23,25-36). Of those, 
18 studies (95%) were conducted prospectively (14,15,17-19,21,23,25-28,30-36) and one 
study retrospectively (29).  All of the included studies reported NT-proBNP and only 2 studies 
included sST2 in their methodology (14,15). 10 articles (43%) reported the association of NT-
proBNP with echocardiographic hemodynamic and structural changes (20,24-26,28-31,33,35). 
4 articles (17%) reported the association of NT-proBNP and exercise capacity (24-26,35). 3 
articles (13%) reported the prognostic value of NT-proBNP for adverse outcomes (15,17,18) 
and 2 articles investigated the levels of NT-proBNP following pulmonary valve replacement 
(PVR) (27,34). Sample size ranged from 16 to 177, and the publication year ranged from 2005 




































































were single centre with different designs. Baseline characteristics of the included studies are 
shown in table 1.  
 
Plasma brain natriuretic peptide level (NT-proBNP) in asymptomatic adult and 
adolescent patients with repaired TOF 
Data was collected on 1479 patients with repaired TOF in 23 studies. Mean age in the total 
population was 22.7±8.3 years. Mean age of the older group was 29±4.5 years and the mean 
age of the younger group was 14±1.1 years. The mean value of NT-proBNP was 174.4.1±56.4 
pg/ml, but ranged from 71.4 to 295 pg/ml. There was no significant difference in mean NT-
proBNP between older and younger subjects (160.4 ±37.7 vs 190.6 ±72.9, pg/ml, respectively; 
p>.05). Mean value of sST2 drawn from two investigations was 26.95 ng/ml (table2). 
 
14 studies (61%) reported NT-proBNP in a population where a trans-annular patch (TAP) was 
used as a surgical approach (15,16,18-21,23,24,26,28,31,33-35). 9 studies (39%) were reported 
in a population with other RVOT intervention, such as pulmonary valvotomy or 
infundibulectomy and/or no reports (14,17,22,25,27,29,30,32,36). Mean NT-proBNP levels 










































































Meta-analysis on the effect of NT-proBNP on cardiovascular outcomes 
 
The prognostic primary outcomes of all-cause mortality, heart failure and sustained ventricular 
arrhythmias occurred in 113 patients, as reported in table 3. Three studies (13%) in 
asymptomatic adult populations investigated the relationship between NT-proBNP and 
cardiovascular outcomes.  The mean NT-proBNP drawn from these investigations was 243± 
113 pg/ml. Heng et al demonstrated that NT-proBNP levels were significantly related to all-
cause mortality with the longest mean observation time of 10 years among the studies (HR 
1.15, 95% CI 1.03-1.28, p<.01). In univariate Cox analysis, the best cut off value of NT-
proBNP level to predict all-cause mortality was 147 pg/ml (AUC .68, P.04) (17).  
 
In the second study elevated NT-proBNP levels were the strongest predictor of other adverse 
outcomes such as sustained ventricular arrhythmias and heart failure, with a mean observation 
time of 6.9 years (HR 2.83, 95% CI 1.1-7.28, P <.029). In multivariate Cox analysis, the best 
cut off value of NT-proBNP level to predict adverse clinical events was 232 pg/ml (AUC .873, 
P.004) (sensitivity of 76.9%, specificity of 85.3%) (18).  
 
In the last study, Laqqan et al reported that elevated NT-proBNP levels were significant 
predictor of all-cause mortality with a mean observation time of two years (HR 1.3, 95% CI 
1.0-1.69, p<.001) (table 3). The authors constructed ROC curves demonstrating the best cut off 
value of NT-proBNP level to predict heart failure, which was 349.5 pg/ml (AUC .875, P.001) 





































































After an average 6.3 years of follow up, high NT-proBNP levels were associated with an 
increased  risk of cardiovascular outcomes including death, arrhythmias and acute heart failure 
with a hazard ratio (HR) of 1.18 (95% CI 1.07-1.31, p.001) (figure 3). 
 
Meta-analysis of the association between NT-proBNP and hemodynamic 
echocardiographic changes 
 
The relationship between NT-proBNP and RV structural, functional and volumetric changes 
was investigated in 10 (43%) articles.  Of these 10 articles, 4 (40%) were reported in the older 
group, while 6 (60%) were reported in the paediatric group. Most of these articles demonstrated 
that elevated NT-proBNP levels were associated with either RV dilatation, higher RV end 
diastolic volumes, RV systolic dysfunction and with severity of pulmonary regurgitation or 
diastolic dysfunction (20,24-26,28-31,33,35). Only three studies (13%) evaluated the 
association between raised levels of NT-proBNP and left ventricular parameters. Higher NT-
proBNP levels were associated with LV dysfunction (18,20), with LV indexed volume (18), 
and with LV indexed dimensions (35). Two studies proposed a cut-off NT-proBNP values of 
145 pg/ml that could predict the presence of RV dilatation (ROC .95, sensitivity 71%, 
specificity 100%) (30), and a value of 115 pg/ml (ROC .87, sensitivity 71%-, specificity 78%) 







































































The meta- analysis showed a statistically significant association of elevated NT-proBNP levels 
to RV size and right ventricular end diastolic volume (RVEDV). The weighted average 
(random effects) correlation coefficient among 10 studies was .41 (95% CI .32-.48, P<.001) 
(table4). The study with the highest correlation was by Cheung et al., 2007 (r=.69, 95% CI .44-
.83, P<.001), however, this study was one of the lowest weighted studies included in the 
analysis, with 31 participants (35). Figure 4a shows the forest plot of pooled correlation 
coefficients. Visual evaluation of the forest plot suggests that there is a mild degree of 
heterogeneity which confirmed by I2 (values of 31.7%, p.15). We observed publication bias by 
Begg's test (p = <.05) or Egger's test (p = <.05) (figure 4b). 
 
There was a strong association between NT-proBNP and the severity of pulmonary 
regurgitation. The pooled analysis showed statistically significant association of elevated NT-
proBNP levels to severity of pulmonary regurgitation in 5 studies (50%) (20,29,30,31,35).  The 
weighted average (random effects) correlation coefficient was .34 (95% CI .16-.50, P<.001). 
Figure 4c shows the forest plot of pooled correlation coefficients. Visual assessment of the 
forest plot suggests a modest degree of heterogeneity, which confirmed by I2 (values of 69.2 
%, p<.05). We observed no publication bias by Begg's test (p= >.05) or Egger's test (p = 








































































Meta-analysis of the association between NT-proBNP and reduced exercise capacity in 
patients with repaired TOF 
 
The relationship between NT-proBNP and exercise intolerance was investigated in 4 articles 
(17%) (24-26,35). Of these 4 articles, 3 (75%) were reported in adults (24-26), while 1 article 
was reported in paediatrics (35). All 4 studies supported the relationship between increased 
NT-proBNP levels and exercise intolerance in asymptomatic patients with repaired TOF 
(table4). 
 
The pooled analysis showed a statistically significant association of elevated NT-proBNP 
levels and reduced exercise capacity in this population. The weighted average (random effects) 
correlation coefficient among 4 studies was -.54 (95% CI -.60- -.36, P<.001) (Table4). Figure 
4e shows the forest plot of pooled correlation coefficients. Visual evaluation of the forest plot 
suggests that there is insignificant degree of heterogeneity which confirmed by I2 (values of 
18.9 %, p>.05). We observed no publication bias by Begg's test (p= >.05) or Egger's test (P = 












































































This systematic review and meta-analysis demonstrate that NT-proBNP levels are generally 
elevated in asymptomatic patients with repaired TOF irrespective of age. It showed that NT-
proBNP is associated with a range of echocardiographic changes including structural RV 
changes, RV volume, severity of pulmonary regurgitation and most importantly the 
deterioration in exercise capacity, clinical condition and mortality. We found that patients with 
a TAP surgical approach had higher values of NT-proBNP compared to other approaches, 
suggesting an adverse hemodynamic response.   
 
Plasma brain natriuretic peptide concentration is known to be high in patients with repaired 
TOF with reference values previously reported as age and gender related (7-11,29,37,38). In 
contrast in this meta-analysis, we found no difference in NT-proBNP levels between adults and 
adolescents (160.4 ±37.7 vs 190.6 ±72.9 pg/ml, p>.05), suggesting that other anatomical and 
functional factors, are more important in these patients. Unlike other pathologies such as LV 
systolic dysfunction, NT-proBNP levels appear to be linked more to RV volumes and surgical 
selection techniques than underlying patient characteristics. This mirrors the finding that 








































































NT-proBNP concentrations correlated with RV structural and volumetric changes in the 
majority of included investigations in this review (20,24-26,28-31,33,35). Our pooled meta-
analysis results revealed a moderate association between NT-proBNP levels and RV structural 
and volumetric changes (r=.41, 95% CI .32-.48, P<.001) (table 4). High concentrations of 
plasma natriuretic peptide are associated with reduced exercise capacity in adult congenital 
heart disease (ACHD), but this has not to date been specifically demonstrated in patients with 
repaired TOF (40). In the studies included in this analysis that evaluated exercise capacity using 
cardiopulmonary exercise testing (CPET), the majority of patients with high levels of NT-
proBNP were asymptomatic, but with reduced exercise capacity (24-26). There were two 
studies that showed contrary findings (19,20). Looking at these study populations, they were 
heavily drawn from populations with low NT-proBNP levels and nearly normal functional 
reserve (124 and 151, pg/ml), and (max VO2 of 80 and 77, %), suggesting that they were biased 
towards the most clinically stable patients. In our pooled meta-analysis, despite relatively fewer 
studies investigating the link between NT-proBNP and exercise capacity, we found a higher 
modest correlation with exercise if it was compared with the structural and volumetric RV 












































































In terms of intervention studies and NT-proBNP, only two investigations in the included 
analysis observed a notable reduction in NT-proBNP levels after 6 months following PVR 
(27,34). These findings may have an important clinical implication that could contribute to the 
complex debate about the decision-making of timing PVR by having an additive value in 
detecting any deterioration in cardiac function and functional capacity (22,41,42). Rare 
documentation of sST2 data which drawn from only two investigations in this review was 
evident and this limits our sST2 assessment in patients with repaired TOF (14,15). A raised 
NT-proBNP could potentially detect early RV dysfunction and identify patients who are in 
need of surgical intervention. This would require identifying specific cut off value of NT-
proBNP which predict adverse outcomes. 
 
The prognostic value of NT-proBNP in adult congenital heart disease has not been widely 
described, and particularly in patients with repaired TOF. Our meta-analysis evaluating the 
prognostic data from three investigations in adults showed that elevated NT-proBNP levels 
(mean of 243± 113 pg/ml) in asymptomatic patients were significantly associated with the 
increased risk of all-cause mortality and major cardiac events, such as acute heart failure, 
sustained ventricular arrhythmias and death (HR of 1.18 (95% CI 1.07-1.31, p.001). NT-
proBNP levels were reported by Laqqan et al as an excellent predictor of adverse outcomes in 
a low-risk population, with an AUC of .875 corresponding to NT-proBNP>349 pg/ml (15). 
This was much greater than the other two studies included with observed prognostic relevance 
(147 and 232 pg/ml) (17,18). This suggests that the magnitude of the mortality deficit is closely 





































































This meta-analysis in 1479 patients with repaired TOF is the first meta-analysis in this group 
with the proposed end points. Currently, evaluation of NT-proBNP levels is not routinely 
assessed for systematic categorisation used in risk assessment in these patients. Although all 
included studies were observational investigations with different methodology, definitive 
conclusions could be drawn. Firstly, our results demonstrate that despite wide variability, 
elevated NT-proBNP levels seems to be more related to surgical selection than advancing age. 
This mirrors our recent publication that showed subsequent exercise intolerance in this 
population is more a function of surgical technique than a function of age (39). Secondly, these 
studies suggests that NT-proBNP is a reliable non-invasive tool as which could improve risk 
stratification in these patients if it is integrated into routine clinical care. Finally, our sub-group 
analysis results of a wide range of NT-proBNP values in relation to hemodynamic changes and 
exercise capacity suggests that the use of blood biomarkers could be more sensitive to other 
existing pathology, which could help in risk assessment in a low-risk population.  Future 
prospective studies will need to investigate the use of index and sequential NT-proBNP 




This systematic review and meta-analysis were limited by inconsistent characteristics of the 
study population, the variability of NT-proBNP with some degree of heterogeneity and the rare 
documentation of sST2. All studies were observational cohorts with limited follow up data but 
with an overall good quality.  Larger prospective and longitudinal studies are warranted to draw 
an accurate prognostic value of NT-proBNP in relation to subsequent hemodynamic changes 






































































Our findings form the first summary and meta-analysis on the prognostic effect of NT-proBNP 
in patients with repaired TOF. We have demonstrated that elevated levels NT-proBNP were 
associated with an increased risk of cardiovascular adverse outcomes that were not age or 
gender related, but seems to be more dependent on surgical selection, the stress on the right 
ventricle and on the subsequent exercise intolerance. NT-proBNP shows promise in improving 
risk assessment and guiding timing for intervention in patients with repaired TOF. 
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Figure1. The PRISMA flow chart displaying the selection of studies and reasons for 
exclusion  
Figure 2. Difference in mean NT-proBNP between TAP and non-TAP studies 
 
Figure 3. Forest plot of the hazard ratios of high NT-proBNP values with cardiovascular 
outcomes in patients with repaired TOF 
 

































































































































































TAP = studies with transannular patch; non-TAP = studies with other type of RVOT intervention such 

























































































































































 (a) Forest plot of the 10 studies evaluated in meta-analysis for the assessment of the association 
between NT-proBNP levels and RV size and RVEDV. (b) Funnel plot of all the 10 studies, where there 
is publication bias.  (c) Forest plot of the 5 studies evaluated in meta-analysis for the assessment of the 
association between NT-proBNP levels and PR. (d) Funnel plot of all the 5 studies, where there is no 
publication bias.  (e) Forest plot of the 4 studies evaluated in meta-analysis for the assessment of the 
association between NT-proBNP levels and VO2 max. (f) Funnel plot of all the 4 studies, where there 



























































































Author Country  
 




ST2, ng/ml  Clinical Outcomes  
 
Quality assessment  













24 -ST2 was associated with adverse 
cardiovascular events. 









61 28.2±12 164 29.9 -ST2 levels is significantly elevated in 
patient with CHD 
-Elevated NT-proBNP and ST2 levels are 







et al., 2016 
Germany Prospective 
cohort 
81 26.3±7.4 168±148 
 
n/a -NT-proBNP levels and pulmonary 
regurgitation were strong predictors of 
adverse outcomes in asymptomatic patients 
-NT-proBNP levels were associated with LV 




















286±269.2 n/a -Elevated NT-proBNP levels were 
associated with right ventricular function and 
exercise intolerance. 
-Elevated NT-proBNP levels were 








40 14.3±6.7 175±109 n/a 
 
-NT-proBNP levels were associated with RV 
dilatation and PR 
-NT-proBNP >145 pg/ml could predict the 












94 32.8±9.5 124±221 n/a -Elevated NT-proBNP level, 














147 ±254 n/a -Elevated levels of NT-proBNP in 
asymptomatic TOF patients. 
- NT-proBNP >132 pg/ml was a predictive 








Cross sectional 177 34.6±11.
8 
151±317 n/a -Elevated NT-proBNP levels were 
associated with LV dysfunction, RVD and 
significant PR 









Cross sectional 51 21±8 132±94 n/a -Elevated NT-proBNP levels were 




      Poor quality 




130 16.1±7.1 200 ±110 n/a -Elevated NT-proBNP levels. 
-Elevated NT-proBNP levels were correlated 










49 14.7 211±219 n/a -Elevated NT-proBNP levels were 
associated with RVD, diastolic dysfunction 
and severity of PR 
 
 
Moderate quality  












21 35 168±92 n/a -Elevated NT-proBNP levels in 







21 12.1±2.5  
295.75±389.11 
n/a -Elevated NT-proBNP levels were 
associated with RVD, RVEDV and 
dysfunction 
-NT-proBNP>115 pg/ml could be used as a 













n/a -Elevated NT-proBNP levels were 
associated with RV volume overload and 






































































Vo2 = maximum predicted oxygen uptake; PVR= pulmonary valve replacement; PR= Pulmonary regurgitation; 
RVD= Right ventricular dimensions; RVEDV= right ventricular end diastolic volume; RVS’= right ventricular 
peak systolic velocity; N/A= not available.  
 
 
Table2. Baseline characteristic of population included. 
TAP= Transannular patch; N/A = Not available.  















23 13.2 231±228 n/a -Elevated NT-proBNP levels in 
asymptomatic patients with chronic PR. 
-NT-proBNP levels were significantly 








59 30±8 150±141 n/a -NT-proBNP levels could be replaced (Vo2, 
%) max to re-stratify CHD patients with 
impaired cardiac function 
 
Moderate quality 
  Exercise 
investigations 
        















70 21±1 218±283 
 
n/a -Elevated NT-proBNP levels were 
associated with RVD, function and RVEDV 
and with exercise intolerance 
 
Moderate quality 




32 14.7±3.1 154 
 
n/a -Elevated NT-proBNP levels were 









60 27.6±8.2 250±200 n/a -Elevated NT-proBNP levels were 
associated with exercise intolerance 
 
Moderate quality 




50 27.8±1.7 164±23 n/a -Elevated NT-proBNP levels were 




Baseline characteristics  N=1479 patients Older (13 studies) Younger (10studies) P value 
Age±SD, years  22.7±8.3 29±4.5 14±1.1 <.05 
NT-proBNP, pg/ml 174.4.1±56.4 160.4±37.7 190.6 ±72.9 >.05 
sST2, ng/ml 26.95* n/a n/a n/a 
Surgical type TAP (14) Non-TAP (9) - P value 
















































































Table 4. Studies included into pooled meta-analysis of the correlation coefficients. 






        
Follow up 
(years) 
Cardiovascular events  
Heng et al., 
2014 




2 sudden cardiac death 
2 perioperative right ventricular failure 
1 severe Aortic stenosis  
1 respiratory sepsis 
1 unknown  
Weshoff-
Bleck et al., 
2016 
81 26.3+7.4 232±175 6.9+2.6 13  
sustained supraventricular arrhythmias or 
heart failure  
 
Laqqan et al., 
2018 





Major adverse cardiac events, defined 
as the occurrence of acute heart failure or 




































































RVD=Right ventricular dimensions; RVS’=right ventricular peak systolic velocity PR= pulmonary 
regurgitation; LVEDVI= Left ventricular end diastolic volume index; RVEDV=right ventricular end 
diastolic volume; N/A= not available.  
*Correlation coefficient between NT-proBNP and RVD and RVEDV.  
** Correlation coefficient between NT-proBNP and severity of pulmonary regurgitation. 
*** Correlation coefficient between NT-proBNP and Vo2 max. 
**** Correlation coefficient between NT-proBNP and LV dysfunction. 
***** Correlation coefficient between NT-proBNP and LV end diastolic volume index. 
****** Correlation coefficient between NT-proBNP and LV indexed dimensions. 
Study N number  Correlation coefficients, r (95% CI) P.value  Association conclusions  




-With RVD and RVS’ 
Koch et al., 2010 130 r= 0.29 (0.124-0.440)* 





-With RVD and severity of PR 
 
Valverde et al., 2015 40 r= 0.54 (0.275-0.729)* 




-With RVD and severity of PR 
Westhoff-bleck et al., 
2016 
81 r= -.412**** 
r= 0.019 ***** 
p<.05 -With LV dysfunction and not with 
RV structural changes 
-With LVEDVI 
Eindhoven et al., 2014 177 r = 0.27 (0.128-0.402)* 
r = 0.19 (0.0437-0.328)** 
r = - 0.367**** 
p<.001 
 
-With RVD and severity of PR  
-With LV dysfunction 
 
Tatani et al., 2010 49 r = 0.41 (0.146-0.620)* 




-With RVD, diastolic dysfunction 
and severity of PR  
 
Khositseth et al., 2007 21 r = 0.57 (0.183-0.804)* p<.001 
 
-With RVD, RVEDV and 
dysfunction 
 
Festa et al., 2007 
 
70 r = 0.40 (0.182-0.580)* 
  r = - 0.52 (-0.673- -0.325)*** 
p<.001 
 
-With RVD, systolic function and 
RVEDV 
-With exercise capacity 
Norozi et al., 2005  50 r = .42 (0.160-0.625)* 
r = -.63 (-0.773- -0.426)*** 
p<.001 
 
-With RVD, RVS’. 
-With exercise capacity 
 
 
Cheung et al., 2007 32 r = 0.69 (0.449-0.837)* 
r = 0.54 (0.236-0.748)** 
r = -0.43 (-0.677- -0.0956)*** 
r = .47, p.006****** 
p<.001 
 
-With RVD, RVEDV and severity 
of PR 
-With exercise capacity 
-With LV Indexed dimensions 
  
Trojnarska et al., 2006 60 r = .45 (0.221-0.632)* 








- -NT-proBNP & RV structural 
changes=.41 (95% CI .32-.48)* 
-NT-proBNP & severity of PR =.34 (95% 
CI .16-.50)** 




-Moderate correlation between 
NT-proBNP and RV structural 
and hemodynamic changes 
 
-Higher moderate correlation 
with reduced exercise capacity 
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